Clinical Trials Logo

Metastatic Cancer clinical trials

View clinical trials related to Metastatic Cancer.

Filter by:

NCT ID: NCT00003884 Completed - Pain Clinical Trials

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Start date: August 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing disease progression. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in treating patients who have solid tumors that have spread to the bone.

NCT ID: NCT00003878 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Carmustine Implants in Treating Patients With Brain Metastases

Start date: April 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.

NCT ID: NCT00003834 Completed - Colorectal Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with liver metastases from colorectal cancer.

NCT ID: NCT00003753 Completed - Colorectal Cancer Clinical Trials

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer

Start date: September 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die. Hepatic arterial infusion uses a catheter to deliver chemotherapy directly to the liver. Combining more than one drug and giving them in different ways may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of irinotecan combined with hepatic arterial infusion with floxuridine and dexamethasone after surgery in treating patients who have liver metastases from colorectal cancer.

NCT ID: NCT00003724 Completed - Metastatic Cancer Clinical Trials

Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases

Start date: February 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Video-assisted surgery may have fewer side effects than conventional surgery in patients with lung metastases. It is not yet known whether conventional surgery or video-assisted surgery is more effective in treating lung metastases. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional surgery with that of video-assisted surgery in treating patients who have lung metastases.

NCT ID: NCT00003714 Withdrawn - Metastatic Cancer Clinical Trials

Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have unresectable primary or metastatic kidney cancer that has not been previously treated.

NCT ID: NCT00003712 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

CCI-779 in Treating Patients With Advanced Solid Tumors

Start date: January 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.

NCT ID: NCT00003563 Completed - Metastatic Cancer Clinical Trials

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

Start date: August 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gadolinium texaphyrin may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation. It is not yet known whether giving gadolinium texaphyrin with radiation therapy is more effective than radiation therapy alone in treating brain metastases. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without gadolinium texaphyrin in treating patients who have brain metastases.

NCT ID: NCT00003461 Completed - Metastatic Cancer Clinical Trials

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

Start date: February 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients with primary or metastatic brain tumors.

NCT ID: NCT00003433 Completed - Colorectal Cancer Clinical Trials

Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

Start date: June 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer.